Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04063267 · ClinicalTrials.gov registry record · Phase 2
Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT04063267: Completed Phase 2 study, sponsored by NYU Langone Health.
NCT04063267 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 48 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04063267, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
Patients in addiction treatment have exceptionally higher rate of cigarette smoking and very low quit rates compared to the general population. The purpose of this study is to examine the feasibility of using e-cigarettes as a method for harm reduction and the effects of providing e-cigarettes (or placebo e-cigarettes) on smoking outcomes among patients in addiction treatment.
Primary Outcome
proportion of participants who achieve 50% reduction in CPD at 3 weeks.
Interventions
- OTHER Nicotine Replacement Therapy
- OTHER E cigarettes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-10-27 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 2 |
What the finished NCT04063267 record still lists
NCT04063267 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which Nicotine Replacement Therapy is the first listed.
NCT04063267 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04063267 about?
NCT04063267 is a clinical study titled "Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder". Patients in addiction treatment have exceptionally higher rate of cigarette smoking and very low quit rates compared to the general population. The purpose of this study is to examine the feasibility of using e-cigarettes as a method for harm reduction and the effects of providing e-cigarettes (or p...
What is the current status of trial NCT04063267?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-10-27. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT04063267?
The interventions under investigation include: Nicotine Replacement Therapy (OTHER), E cigarettes (OTHER).
Who is sponsoring clinical trial NCT04063267?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04063267's enrollment target sits among peer trials
48 1265th of 2000 higher than 718 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI